Resmed Historical Cash Flow

RMD Stock

38.19 0.13 0.34%

Analysis of Resmed cash flow over time is an excellent tool to project Resmed Inc DRC future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 325.3 M or Depreciation of 227 M as it is a great indicator of Resmed ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Resmed Inc DRC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Resmed Inc DRC is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Resmed Inc DRC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Resmed Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Resmed balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Resmed's non-liquid assets can be easily converted into cash.

Resmed Cash Flow Chart

At this time, Resmed's End Period Cash Flow is comparatively stable compared to the past year. Net Borrowings is likely to gain to about 803 M in 2024, whereas Capital Expenditures is likely to drop slightly above 66.9 M in 2024.

Begin Period Cash Flow Capital Expenditures Net Income Dividends Paid

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Resmed Inc DRC to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Resmed operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Resmed Inc DRC financial statement analysis. It represents the amount of money remaining after all of Resmed Inc DRC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Dividends Paid

The total amount of dividends that a company has paid out to its shareholders over a specific period.

Most accounts from Resmed's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Resmed Inc DRC current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Resmed Inc DRC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2020	2022	2023	2024 (projected)
Dividends Paid	245.3M	258.3M	282.3M	205.5M
Stock Based Compensation	65.3M	71.1M	80.2M	41.0M

Dividends Paid Stock Based Compensation

Resmed cash flow statement Correlations

	Change To Inventory	Change In Cash	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Capital Expenditures	Net Income	End Period Cash Flow	Sale Purchase Of Stock	Stock Based Compensation	Dividends Paid	Change To Account Receivables	Investments	Net Borrowings	Change To Operating Activities	Change To Netincome	Change To Liabilities	Issuance Of Capital Stock
Change To Inventory		0.02	0.58	0.88	0.1	-0.05	0.29	-0.51	0.03	0.12	-0.45	-0.25	-0.13	-0.44	0.11	0.14	0.25	-0.22	0.43	0.0
Change In Cash	0.02		0.1	-0.05	-0.33	0.05	-0.01	0.04	0.14	0.33	-0.01	-0.02	-0.01	0.21	-0.06	0.41	0.42	0.05	-0.56	0.28
Free Cash Flow	0.58	0.1		0.27	-0.25	0.74	0.67	0.28	0.81	-0.19	-0.2	0.49	0.51	-0.6	-0.23	0.44	-0.44	0.45	0.2	0.72
Change In Working Capital	0.88	-0.05	0.27		0.31	-0.35	-0.08	-0.67	-0.34	0.27	-0.5	-0.4	-0.28	-0.25	0.15	-0.11	0.52	-0.4	0.64	-0.36
Begin Period Cash Flow	0.1	-0.33	-0.25	0.31		-0.41	-0.54	-0.14	-0.39	0.78	-0.22	-0.14	-0.09	0.07	0.09	-0.38	0.35	-0.57	0.35	-0.58
Depreciation	-0.05	0.05	0.74	-0.35	-0.41		0.65	0.77	0.91	-0.38	0.2	0.81	0.79	-0.39	-0.2	0.3	-0.75	0.82	-0.07	0.8
Other Non Cash Items	0.29	-0.01	0.67	-0.08	-0.54	0.65		0.27	0.66	-0.55	0.39	0.36	0.21	-0.43	-0.08	0.34	-0.59	0.63	-0.09	0.64
Capital Expenditures	-0.51	0.04	0.28	-0.67	-0.14	0.77	0.27		0.68	-0.11	0.29	0.9	0.74	-0.09	-0.21	0.09	-0.63	0.64	-0.26	0.59
Net Income	0.03	0.14	0.81	-0.34	-0.39	0.91	0.66	0.68		-0.29	0.05	0.7	0.64	-0.46	-0.34	0.51	-0.72	0.61	-0.21	0.92
End Period Cash Flow	0.12	0.33	-0.19	0.27	0.78	-0.38	-0.55	-0.11	-0.29		-0.22	-0.15	-0.1	0.2	0.06	-0.1	0.62	-0.54	-0.02	-0.4
Sale Purchase Of Stock	-0.45	-0.01	-0.2	-0.5	-0.22	0.2	0.39	0.29	0.05	-0.22		0.2	0.02	0.02	0.09	-0.17	-0.27	0.43	-0.18	0.04
Stock Based Compensation	-0.25	-0.02	0.49	-0.4	-0.14	0.81	0.36	0.9	0.7	-0.15	0.2		0.8	-0.22	-0.26	0.21	-0.6	0.71	-0.01	0.58
Dividends Paid	-0.13	-0.01	0.51	-0.28	-0.09	0.79	0.21	0.74	0.64	-0.1	0.02	0.8		-0.22	-0.18	0.18	-0.55	0.62	-0.01	0.51
Change To Account Receivables	-0.44	0.21	-0.6	-0.25	0.07	-0.39	-0.43	-0.09	-0.46	0.2	0.02	-0.22	-0.22		0.28	-0.25	0.24	0.01	-0.48	-0.29
Investments	0.11	-0.06	-0.23	0.15	0.09	-0.2	-0.08	-0.21	-0.34	0.06	0.09	-0.26	-0.18	0.28		-0.6	0.13	-0.08	-0.06	-0.29
Net Borrowings	0.14	0.41	0.44	-0.11	-0.38	0.3	0.34	0.09	0.51	-0.1	-0.17	0.21	0.18	-0.25	-0.6		-0.04	0.15	-0.38	0.45
Change To Operating Activities	0.25	0.42	-0.44	0.52	0.35	-0.75	-0.59	-0.63	-0.72	0.62	-0.27	-0.6	-0.55	0.24	0.13	-0.04		-0.67	0.08	-0.69
Change To Netincome	-0.22	0.05	0.45	-0.4	-0.57	0.82	0.63	0.64	0.61	-0.54	0.43	0.71	0.62	0.01	-0.08	0.15	-0.67		-0.14	0.59
Change To Liabilities	0.43	-0.56	0.2	0.64	0.35	-0.07	-0.09	-0.26	-0.21	-0.02	-0.18	-0.01	-0.01	-0.48	-0.06	-0.38	0.08	-0.14		-0.33
Issuance Of Capital Stock	0.0	0.28	0.72	-0.36	-0.58	0.8	0.64	0.59	0.92	-0.4	0.04	0.58	0.51	-0.29	-0.29	0.45	-0.69	0.59	-0.33

Click cells to compare fundamentals

Resmed Account Relationship Matchups

Resmed cash flow statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Change To Inventory	(69.9M)	(22.0M)	(311.7M)	(248.8M)	172.2M	180.8M
Change In Cash	316.0M	(167.9M)	(21.6M)	(45.8M)	10.5M	6.0M
Free Cash Flow	696.3M	619.9M	195.1M	559.3M	1.3B	1.4B
Change In Working Capital	(97.9M)	1.4M	(708.1M)	(462.1M)	44.8M	47.0M
Begin Period Cash Flow	147.1M	463.2M	295.3M	273.7M	227.9M	325.3M
Other Cashflows From Financing Activities	(46.4M)	(53.7M)	(52.4M)	(33.0M)	(10.1M)	(10.6M)
Depreciation	181.4M	191.5M	193.8M	197.6M	216.2M	227.0M
Other Non Cash Items	(7K)	8.7M	20.7M	(11.1M)	39.1M	41.1M
Capital Expenditures	105.9M	116.8M	156.0M	134M	114.9M	66.9M
Total Cash From Operating Activities	802.3M	736.7M	351.1M	693.3M	1.4B	1.5B
Net Income	621.7M	474.5M	779.4M	897.6M	1.0B	1.1B
End Period Cash Flow	463.2M	295.3M	273.7M	227.9M	238.4M	333.5M
Sale Purchase Of Stock	(50.2M)	90M	288M	(30.6M)	(150.0M)	(142.5M)
Stock Based Compensation	57.6M	63.9M	65.3M	71.1M	80.2M	41.0M
Dividends Paid	225.1M	226.7M	245.3M	258.3M	282.3M	205.5M
Change To Account Receivables	54.4M	(129.2M)	19.3M	(106.5M)	(134.3M)	(127.6M)
Investments	(31.6M)	(21.8M)	(13.9M)	(1.2B)	(269.8M)	(283.3M)
Net Borrowings	(94.0M)	(522M)	122M	665M	764.8M	803.0M
Total Cashflows From Investing Activities	(179.9M)	(158.5M)	(229.9M)	(1.2B)	(1.0B)	(991.7M)
Change To Operating Activities	(59.0M)	(58.2M)	(168.1M)	(138.1M)	(124.3M)	(118.1M)
Other Cashflows From Investing Activities	(14.4M)	19.2M	(17.2M)	(1.0B)	(923.3M)	(877.1M)
Change To Netincome	97.1M	74.4M	85.9M	60.3M	69.4M	65.8M
Change To Liabilities	(23.4M)	210.7M	(247.6M)	31.3M	28.2M	24.6M
Issuance Of Capital Stock	48.2M	37.8M	47.4M	49.1M	53.1M	49.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Resmed Stock Analysis

When running Resmed's price analysis, check to measure Resmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Resmed is operating at the current time. Most of Resmed's value examination focuses on studying past and present price action to predict the probability of Resmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Resmed's price. Additionally, you may evaluate how the addition of Resmed to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC